CEO Says Sanofi Can Mass-Produce Hydroxychloroquine for COVID-19 Patients
Sanofi (NASDAQ: SNY) CEO Paul Hudson said that his company is ready, willing and able to produce a drug that seems to be efficacious in treating COVID-19, the disease that can result from the rapidly spreading SARS-CoV-2 coronavirus.
In an interview with Reuters published Thursday, Hudson claimed that Sanofi has the capability to make and distribute millions of doses of hydroxychloroquine if the drug is successful against COVID-19 in clinical trials. A more precise number was not provided.
Although hydroxychloroquine is a decades-old drug used chiefly to treat malaria -- which caused by a parasite, not a virus -- several limited-scale studies have indicated that it may be effective against COVID-19. But more testing will be required for a fuller understanding.
Source Fool.com
